RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Satsuma Pharmaceuticals Stock

Satsuma Pharmaceuticals Revenue 2024

Satsuma Pharmaceuticals Revenue

3.83 M USD

Ticker

STSA

ISIN

US80405P1075

WKN

A2PQPD

In 2024, Satsuma Pharmaceuticals's sales reached 3.83 M USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Satsuma Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e27.32-
2028e34.52-
2027e31.37-
2026e20.68-
2025e15.07-
2024e3.83-
2023e--
2022--
2021--
2020--
2019--
2018--
2017--

Satsuma Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Satsuma Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Satsuma Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Satsuma Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Satsuma Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Satsuma Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Satsuma Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Satsuma Pharmaceuticals’s growth potential.

Satsuma Pharmaceuticals Revenue, EBIT and net profit per share

DateSatsuma Pharmaceuticals RevenueSatsuma Pharmaceuticals EBITSatsuma Pharmaceuticals Net Income
2029e27.32 M undefined0 undefined3.38 M undefined
2028e34.52 M undefined19.8 M undefined2.37 M undefined
2027e31.37 M undefined6.03 M undefined1.01 M undefined
2026e20.68 M undefined-284,916.6 undefined-2.03 M undefined
2025e15.07 M undefined-39.91 M undefined-10.74 M undefined
2024e3.83 M undefined-28.42 M undefined-19.78 M undefined
2023e0 undefined-33.7 M undefined-31.53 M undefined
20220 undefined-59.22 M undefined-70.06 M undefined
20210 undefined-51.17 M undefined-51.17 M undefined
20200 undefined-48.33 M undefined-47.56 M undefined
20190 undefined-28.88 M undefined-28.18 M undefined
20180 undefined-7.52 M undefined-7.35 M undefined
20170 undefined-4.95 M undefined-5.17 M undefined

Satsuma Pharmaceuticals stock margins

The Satsuma Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Satsuma Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Satsuma Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Satsuma Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Satsuma Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Satsuma Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Satsuma Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Satsuma Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Satsuma Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Satsuma Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Satsuma Pharmaceuticals Margin History

Satsuma Pharmaceuticals Gross marginSatsuma Pharmaceuticals Profit marginSatsuma Pharmaceuticals EBIT marginSatsuma Pharmaceuticals Profit margin
2029e0 %0 %12.38 %
2028e0 %57.35 %6.86 %
2027e0 %19.22 %3.23 %
2026e0 %-1.38 %-9.81 %
2025e0 %-264.76 %-71.22 %
2024e0 %-742.14 %-516.5 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Satsuma Pharmaceuticals Aktienanalyse

What does Satsuma Pharmaceuticals do?

Satsuma Pharmaceuticals Inc is a young company that was founded in 2016. The company is a biotechnology company specializing in the development and commercialization of medications for the treatment of migraines. Its headquarters are located in South San Francisco, California. The business model of Satsuma Pharmaceuticals is based on the development of medications for the treatment of migraines. The company uses the latest research findings to develop more effective treatment options for patients with migraines. Migraine is one of the most common neurological disorders worldwide. It is estimated that approximately 1 billion people worldwide suffer from this disease, with women being more commonly affected than men due to hormonal differences. Satsuma Pharmaceuticals aims to combat this widespread disease by reducing the severity and frequency of migraine attacks for patients. To achieve its goals, Satsuma Pharmaceuticals has developed a technology platform that enables the development of new medications for the treatment of migraines. This platform is based on the latest developments in medication development and includes various areas such as drug research, preclinical development, clinical development, and approval processes. Satsuma Pharmaceuticals closely collaborates with leading physicians and researchers to develop its medications. The company conducts clinical trials to evaluate the effectiveness and safety of its medications and hopes to soon bring its first products to the market. Currently, Satsuma Pharmaceuticals is focused on the clinical development of a medication called STS101 for the treatment of migraines. This medication is a combination of an already established migraine medication and a new formulation technology. STS101 aims to quickly and effectively treat migraine attacks, thus improving the quality of life for patients with migraines. The company believes that STS101 represents a significant breakthrough in the treatment of migraines. Overall, Satsuma Pharmaceuticals is a promising company that has focused on combating one of the most common neurological disorders in the world. Through close collaboration with leading researchers and physicians, as well as new technology platforms, the company has the potential to make significant advancements in the development of medications for the treatment of migraines and thus improve the lives of millions of people worldwide. Satsuma Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Satsuma Pharmaceuticals's Sales Figures

The sales figures of Satsuma Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Satsuma Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Satsuma Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Satsuma Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Satsuma Pharmaceuticals stock

How much revenue did Satsuma Pharmaceuticals generate this year?

Satsuma Pharmaceuticals has achieved a revenue of 3.83 M USD this year.

How much was the turnover of the company Satsuma Pharmaceuticals compared to the previous year?

The revenue of Satsuma Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Satsuma Pharmaceuticals?

The revenue of Satsuma Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Satsuma Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Satsuma Pharmaceuticals so important for investors?

The revenue of Satsuma Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Satsuma Pharmaceuticals pay?

Over the past 12 months, Satsuma Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Satsuma Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Satsuma Pharmaceuticals?

The current dividend yield of Satsuma Pharmaceuticals is .

When does Satsuma Pharmaceuticals pay dividends?

Satsuma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, December, March, April.

How secure is the dividend of Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Satsuma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Satsuma Pharmaceuticals located?

Satsuma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Satsuma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Satsuma Pharmaceuticals from 4/15/2014 amounting to 0.2 USD, you needed to have the stock in your portfolio before the ex-date on 3/28/2014.

When did Satsuma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/15/2014.

What was the dividend of Satsuma Pharmaceuticals in the year 2023?

In the year 2023, Satsuma Pharmaceuticals distributed 0 USD as dividends.

In which currency does Satsuma Pharmaceuticals pay out the dividend?

The dividends of Satsuma Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Satsuma Pharmaceuticals

Our stock analysis for Satsuma Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Satsuma Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.